Background
Teligent, a New Jersey-based generic pharmaceutical company, was subject to federal requirements governing manufacturing practices, laboratory controls, and testing. According to the amended complaint, its board never created an oversight committee or implemented a compliance-reporting system focused on FDA requirements, even after learning of possible violations. The board’s Audit Committee focused on SEC compliance, while the FDA issued several inspection-related and warning letters between 2016 and 2021.
Teligent filed for Chapter 11 bankruptcy in October 2021. After the Court of Chancery realigned Teligent as the plaintiff and substituted its plan administrator as the real party in interest, the administrator pursued fiduciary-duty claims against former directors and officers. The claims include Caremark theories based on an alleged failure to establish a reporting system and respond to red flags, a broader loyalty claim, and duty-of-care claims against two officers for allegedly failing to provide the board with information needed for decision-making.
The Court’s Holding
Chancellor McCormick granted in part and denied in part the defendants’ request for leave to file a summary-judgment motion. The court permitted a motion addressing whether the plaintiff’s claims are time-barred and whether the amended claims relate back to the original complaint, reasoning that those arguments did not implicate materially disputed facts.
The court denied leave as to the defendants’ proposed merits argument that the plaintiff’s own documents showed they had not utterly failed to implement a reporting system. The court found that the merits issues were factually intensive, that sufficient evidence supported triable factual disputes, and that summary adjudication would not promote judicial economy. It emphasized that summary judgment may be inappropriate when motive, intent, or other subjective matters are central and when live testimony would assist in evaluating the record.
Key Takeaways
- Defendants may seek summary judgment on whether the claims are untimely and whether the amended complaint relates back.
- Defendants may not pursue summary judgment on the merits of the Caremark reporting-system theory at this stage.
- Delaware courts retain discretion to deny summary adjudication when disputed, fact-intensive issues would benefit from development at trial.
Why It Matters
The ruling leaves the core fiduciary-duty allegations for trial or further factual development while allowing a potentially case-dispositive limitations defense to proceed. It also illustrates the Court of Chancery’s reluctance to resolve fact-heavy oversight claims on a paper record when questions of intent, knowledge, and the practical operation of compliance systems remain disputed.